trending Market Intelligence /marketintelligence/en/news-insights/trending/c5MpgfzbMboEEHS4qkwm2g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche completes $4.3B acquisition of gene therapy developer Spark Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche completes $4.3B acquisition of gene therapy developer Spark Therapeutics

Roche Holding AG has completed the $4.3 billion acquisition of gene therapy developer Spark Therapeutics Inc. after securing all required regulatory approvals.

The Switzerland-based pharmaceutical giant on Dec. 16 concluded a tender offer, which was started in March, to acquire all outstanding shares of Philadelphia-based Spark for $114.50 apiece. Roche also managed to secure approvals from regulators in the U.S. and U.K., after the tender offer had been extended several times in the past months to allow the agencies to look further into the deal.

Spark's shares will no longer trade on the Nasdaq Stock Market, and the company will become a wholly owned unit of Roche. The unit will continue to operate independently within the Roche Group, according to a Dec. 17 press release.

Roche initially offered to buy Spark in February, with closing originally expected in the second quarter.